Kamada Ltd (IL:KMDA) has released an update.
Kamada Ltd. has reported a robust start to 2024, showcasing a 23% increase in first-quarter revenues, which amounted to $37.7 million, and a significant 96% surge in adjusted EBITDA to $7.5 million. The company’s positive performance, driven by strong U.S. sales of KEDRAB® and CYTOGAM®, has led to an upward revision of its full-year revenue and EBITDA forecasts. Kamada remains focused on growth, leveraging financial strength to explore new business opportunities and expecting double-digit growth rates to continue beyond 2024.
For further insights into IL:KMDA stock, check out TipRanks’ Stock Analysis page.
